Intellia Therapeutics Inc. (NASDAQ:NTLA) went down by -3.53% during the previous trading session, and it is maintaining the win ahead of Wednesday’s trading session. The share price of the Biotechnology giant went up by $21.59 to trade ended Wednesday trading at $22.38. This is down from the $22.38 price recorded on Tuesday’s trading session. Its performance from the start of the year has also been positive, with NTLA up by 47.17% year-to-date.
Intellia Therapeutics Inc. (NTLA) started the day trading at $22.39 and recorded an intraday high of $23.58. It also recorded an intraday low of $21.47 during Wednesday’s trading session. Intellia Therapeutics Inc. is a very active stock that recorded a trading volume that is more than 13.44% of the average daily trading volume on Wednesday. The stock’s trading volume on Wednesday was 1056092, which is more than 13.44 of the total average daily trading volume of 914.18K.
Intellia Therapeutics Inc. (NASDAQ:NTLA) 2020 Performance Impressive
The increase in NTLA’s stock price on Wednesday saw its overall performance boost over the past few months. We can quantify the performance of the stock so far this year using a few metrics. The 52-week high price of NTLA currently stands at $24.32, which is higher than the current trading price of the stock by 11.23%. However, NTLA’s current trading price is -135.19% lower than the 52-week low price of $9.18. In terms of trading volume, Intellia Therapeutics Inc. currently experienced healthy participation during the last trading session. 1056092 shares of Intellia Therapeutics Inc. were traded on the stock exchange on Wednesday, which is more than 13.44% of the 914.18K average trading volume of the stock.
The performance of the stock has been positive over the past year. NTLA’s performance over the past one year has seen it surge by 45.00%, while the stock has gone up by 36.47% in the last six months. The quarterly performance of NTLA currently stands at 69.07%, and it is up by 13.04% in the last month. The only positive figure was from the weekly performance, which currently reads 3.80%. At the time of writing NTLA’s report, the company has a total market cap of $1.19B, making it one of the largest publicly-traded companies in the world.Intellia Therapeutics Inc. also has over 270 employees all over the world.
NTLA Insider Activities
For Intellia Therapeutics Inc., insiders hold 71.80% of all company shares. The insider transactions over the past six months are down by -164.90%. During that period, insiders bought 25,000 shares in 3 transactions. In that same period, insiders sold 16,230 of their shares in 3 transactions. After these transactions, insiders at Intellia Therapeutics Inc. now hold 9.77M shares, which is over 76.41% of the total company stocks. Institutional investors currently hold a large chunk of the NTLA shares, as they control 19.02% of the company’s total stock.
NTLA Fundamental Analysis
For Intellia Therapeutics Inc., the stock’s diluted earnings per share (EPS) stands at -2.25. In the coming year, analysts expect the EPS to be -2.91. The EPS growth will up over the next five years to 30.00% after plunging by -50.60% in the previous five years. In terms of revenue, Intellia Therapeutics Inc.’s quarterly sales (YOY) is shrinking at -0.69, which is higher than the average annual revenue of -50.60% over the past half a decade.
NTLA Analysts Prediction
Analysts at Wedbush believe that NTLA is Outperform, and they have a price target of between $20 and $21. Jefferies and Jefferies also believe that Intellia Therapeutics Inc.’s stock is outperforming at the moment.
NTLA Technical Analysis
The Simple Moving Average (SMA) is one of the most powerful technical indicators. The 20-day Simple Moving Average of NTLA currently stands at 6.38%, while the SMA50 is 24.45%. The biggest one is the SMA200, which is currently reading 47.98% ahead of Wednesday’s trading session. The Relative Strength Index of this stock is 58.15.